Study on the Protective Effect of Platelet-Rich Plasma Combined with Injection of Pain Points Around Knee Joint on Knee Osteoarthritis and its Molecular Mechanism

Altern Ther Health Med. 2023 Nov 17:AT9814. Online ahead of print.

Abstract

Objective: Previous studies showed the PRP have the therapeutic effects for KOA, but the more detail roles remained unclear and therefore this study was carried on to explore the deeper mechanisms for PRP.

Methods: NRS and WOMAC scores were used to evaluate the clinical efficacy before surgery, 1 month and 6 months after surgery, and the postoperative joint structure changes (n = 24). Examination of pathology of the femoral condyle plate in rats using HE staining (n = 6); Angiogenesis experiments were used to investigate the effect of different groups of cell culture supernatants on the tubular structure formation capacity of HUVECs (n = 3). Observe the proliferation of chondrocytes using clonal formation experiments (n = 3). Western blot was used to analyze the PI3K/AKT signaling pathway and the expression of exosome-secretion-related proteins (n = 3).

Results: In clinical studies, PRP can reduce patients' NRS and WOMAC scores and alleviate the progression of knee arthritis; In rat experiments, PRP reduced damage from knee arthritis and lowered Mankin's score. PRP improves tubular formation of HUVECs and the proliferation capacity of chondrocytes. Compared with the blank control group, the protein expression levels of PI3K, AKT, mTOR, P27, and cyclinD1 in the PRP group were increased. Compared with the PRP group, the protein expression levels of PI3K, AKT, mTOR, P27, and cyclinD1 in the PRP+Axitinib group supplemented with VEGFRs inhibitor and PI3K inhibitor group were significantly decreased. The effect of the LY294002 +PRP group was better than that of the above groups. Macrophage-derived exosomes activate HIF-1a and COX-2 in endothelial cells to promote chondrocyte repair of KOA.

Conclusion: PRP can promote chondrocytes proliferation and repair by activating the PI3K/AKT signaling pathway, thereby exerting anti-OA effects. It provides new targets and methods for the clinical treatment of OA.